Therapeutic Effect of Anti-Inflammatory Tripeptide Cream in Hand-Foot Syndrome/Skin Reaction Related to Anticancer Drugs: a Randomized, Double-Blind, Placebo-Controlled Pilot Trial

키워드

참고문헌 (30)

1. Chen J, "How to conduct integrated pharmaceutical care for patients with hand-foot syndrome associated with chemotherapeutic agents and targeted drugs", J Oncol Pharm Pract, 27, pp.919~929 (2021)
2. Miller KK, "Chemotherapy-induced hand-foot syndrome and nail changes : a review of clinical presentation, etiology, pathogenesis, and management", J Am Acad Dermatol, 71, pp.787~794 (2014)
3. Degen A, "The hand-foot-syndrome associated with medical tumor therapy : classification and management", J Dtsch Dermatol Ges, 8, pp.652~661 (2010)
4. Lou Y, "Possible pathways of capecitabine-induced hand-foot syndrome", Chem Res Toxicol, 29, pp.1591~1601 (2016)
5. "Product: Binterin Solution 400-W" (2023)[URL]
6. "Product: Winhibin Solution 200"[URL]
7. Lee KJ, "CD99-derived agonist ligands inhibit fibronectin-induced activation of beta1 integrin through the protein kinase A", SHP2, PTPN12, pp.focal adhesion kinase signaling pathway, Mol Cell Biol[DOI]
8. Zou DP, "SFRP5 inhibits melanin synthesis of melanocytes in vitiligo by suppressing the Wnt", beta-catenin signaling, 2021, pp.8, 677~688
9. Liu J, "Wnt", beta-catenin signalling : function, biological mechanisms, and therapeutic opportunities, 2022, pp.7, 3~
10. Bos JD, "The 500 Dalton rule for the skin penetration of chemical compounds and drugs", Exp Dermatol, 9, pp.165~169 (2000)
11. "Common Terminology Criteria for Adverse Events (CTCAE) version 5" (2017)[URL]
12. Anderson RT, "The hand-foot skin reaction and quality of life questionnaire : an assessment tool for oncology", Oncologist, 20, pp.831~838 (2015)
13. Nam SH, "Development and validation of the Korean version of Hand-Foot Skin Reaction and Quality of Life Questionnaire(HF-QoL-K)", J Korean Med Sci, 31, pp.1969~1975 (2016)
14. Kang YK, "Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy : results of a randomi-zed, double-blind, placebo-controlled study", J Clin Oncol, 28, pp.3824~3829 (2010)
15. Zhou Y, "Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome : a meta-analysis", Biomed Rep, 1, pp.873~878 (2013)
16. Chen M, "Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy : a systematic review", PLoS One, 8, pp.e72245~ (2013)
17. Yap YS, "Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome : a randomized clinical trial", JAMA Oncol, 3, pp.1538~1545 (2017)
18. Zhang RX, "Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients : result of a single-center, prospective randomized phase III trial", Ann Oncol, 23, pp.1348~1353 (2012)
19. Chen JC, "Preventive effect of celecoxib in sorafenib-related hand-foot syndrome in hepatocellular carcinoma patients, a single-center, open-label, randomized, controlled clinical phase III trial", Am J Cancer Res, 10, pp.1467~1476 (2020)
20. Macedo LT, "Prevention strategies for chemotherapy-induced hand-foot syndrome : a systematic review and meta-analysis of prospective randomised trials", Support Care Cancer, 22, pp.1585~1593 (2014)
21. Huang XZ, "Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome", Int J Cancer, 142, pp.2567~2577 (2018)
22. Wolf SL, "Placebo-controlled trial to determine the effectiveness of a urea", lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome : North Central Cancer Treatment Group Study N05C5, 2010, pp.28, 5182~5187
23. Hofheinz RD, "Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome : a randomized phase III trial of the AIO Quality of Life Working Group", J Clin Oncol, 33, pp.2444~2449 (2015)
24. Lan TC, "Effect of urea cream on hand-foot syndrome in patients receiving chemotherapy : a meta-analysis", Cancer Nurs, 45, pp.378~386 (2022)
25. Gialaim Purcino Dos Reis FC, "Topical interventions for preventing hand-foot syndrome resulting from antineoplastic therapy : a scoping review", Rev Esc Enferm USP, 57, pp.e20220107~ (2023)
26. Pandy JG, "Prophylactic strategies for hand-foot syndrome", skin reaction associated with systemic cancer treatment : a meta-analysis of randomized controlled trials, 2022, pp.30, 8655~8666
27. Barcella CA, "Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy : a nationwide study in patients with osteoarthritis", Basic Clin Pharmacol Toxicol, 124, pp.629~641 (2019)
28. Garcia-Rayado G, "NSAID induced gastrointestinal damage and designing GI-sparing NSAIDs", Expert Rev Clin Pharmacol, 11, pp.1031~1043 (2018)
29. Harvey J, "The long-term safety of topical corticosteroids in atopic dermatitis : a systematic review", Skin Health Dis, 3, pp.e268~ (2023)
30. Shinohara N, "A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma", Ann Oncol, 25, pp.472~476 (2014)

관련 논문AI추천